The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: Preliminary antitumor activity and pharmacodynamic data.
Paul K. Paik
Research Funding - AstraZeneca; GlaxoSmithKline
Ronglai Shen
No relevant relationships to disclose
David Ferry
Consultant or Advisory Role - AstraZeneca
Jean-Charles Soria
Honoraria - AstraZeneca
Alastair Mathewson
Employment or Leadership Position - AstraZeneca
Elaine Kilgour
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Donal Landers
Employment or Leadership Position - AstraZeneca
Paul Frewer
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Nigel Brooks
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Fabrice Andre
Honoraria - AstraZeneca
Research Funding - AstraZeneca